In Vitro Drug Sensitivity Tests to Predict Molecular Target Drug Responses in Surgically Resected Lung Cancer.

Correction: In Vitro Drug Sensitivity Tests to Predict Molecular Target Drug Responses in Surgically Resected Lung Cancer. PLoS One (2016) 0.75

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78

Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med (2009) 13.47

Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 11.02

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol (2011) 8.40

Understanding diagnostic tests 3: Receiver operating characteristic curves. Acta Paediatr (2007) 6.70

KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res (2009) 6.10

Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res (2005) 2.96

Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One (2009) 2.79

Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol (2013) 2.68

Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer (2007) 1.55

Development of a new in vitro chemosensitivity test using collagen gel droplet embedded culture and image analysis for clinical usefulness. Recent Results Cancer Res (2003) 1.33

An in vitro chemosensitivity test for solid human tumors using collagen gel droplet embedded cultures. Int J Oncol (1997) 1.19

Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. Cancer Sci (2007) 1.12

Advances in target therapy for lung cancer. Jpn J Clin Oncol (2009) 1.07

Clinical evaluation of chemosensitivity testing for patients with unresectable non-small cell lung cancer (NSCLC) using collagen gel droplet embedded culture drug sensitivity test (CD-DST). Cancer Chemother Pharmacol (2006) 1.05

Prediction of chemotherapeutic effect on postoperative recurrence by in vitro anticancer drug sensitivity testing in non-small cell lung cancer patients. Lung Cancer (2009) 1.01

Collagen gel droplet culture method to examine in vitro chemosensitivity. Methods Mol Med (2005) 1.00

Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin Cancer Res (2005) 0.93

A comparison of immunohistochemical assays and FISH in detecting the ALK translocation in diagnostic histological and cytological lung tumor material. J Thorac Oncol (2014) 0.92

Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy. Lung Cancer (2013) 0.92

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer. Cancer Chemother Pharmacol (2013) 0.87

Epidermal growth factor receptor mutation in a patient with squamous cell carcinoma of the lung: who should be tested? Case Rep Oncol (2013) 0.84

Complete response of a patient with advanced primary splenic histiocytic sarcoma by treatment with chemotherapeutic drugs selected using the collagen gel droplet-embedded culture drug sensitivity test. Intern Med (2012) 0.84

Histoculture drug response assay for gefitinib in non-small-cell lung cancer. Gen Thorac Cardiovasc Surg (2009) 0.82

Insufficient effect of p27(KIP1) to inhibit cyclin D1 in human esophageal cancer in vitro. Int J Oncol (2001) 0.82

Association of epidermal growth factor receptor mutations in lung cancer with chemosensitivity to gefitinib in isolated cancer cells from Japanese patients. Eur J Cancer Care (Engl) (2007) 0.79

Antitumor chemosensitivity differs between clinical sarcoma and adenocarcinoma tissues. Anticancer Res (1994) 0.79

The succinate dehydrogenase inhibition test for evaluating biopsy specimens and resected tumors of advanced gastric cancer. Surg Today (1992) 0.78